Protalix BioTherapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $51.8 million, 98% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
81
|
53
|
53
|
65
|
48
|
38
|
63
|
55
|
—
|
21
|
9
|
| Product |
54
-12.7%
share 66.5%
|
52
-2.2%
share 98.2%
|
53
+31.1%
share 99.2%
|
40
+59.8%
share 61.7%
|
25
+51.0%
share 53.1%
|
17
+3.2%
share 43.7%
|
16
+2.3%
share 25.8%
|
16
share 29.0%
|
—
|
—
|
—
|
| License And Service |
27
+5164.1%
share 33.5%
|
1
+125.4%
share 1.8%
|
0
-98.3%
share 0.8%
|
25
+12.2%
share 38.3%
|
22
+3.4%
share 46.9%
|
22
-53.7%
share 56.3%
|
47
+20.2%
share 74.2%
|
39
share 71.0%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PLX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hackensack, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006281
- Former names
- ORTHODONTIX INC (until Feb 22, 2007); EMBASSY ACQUISITION CORP (until Mar 31, 1998)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.